Multicenter randomized phase III trial of Epirubicin plus Paclitaxel vs Epirubicin followed by Paclitaxel in metastatic breast cancer patients: focus on cardiac safety

The aim of the study was to evaluate cardiac safety of two different schedules of Epirubicin and Paclitaxel in advanced breast cancer patients enrolled into a multicenter randomized phase III trial. Patients received Epirubicin 90 mg m(−2) plus Paclitaxel 200 mg m(−2) (3-h infusion) on day 1 every 3...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Baldini, E, Prochilo, T, Salvadori, B, Bolognesi, A, Aldrighetti, D, Venturini, M, Rosso, R, Carnino, F, Gallo, L, Giannessi, P, Conte, P F, Orlandini, C, Bruzzi, P
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2004
Assuntos:
Clinical
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2364750/
https://ncbi.nlm.nih.gov/pubmed/15173858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601883
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados